Osmotica Pharmaceuticals Net Income 2017-2021 | OSMT

Osmotica Pharmaceuticals net income from 2017 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Osmotica Pharmaceuticals Annual Net Income
(Millions of US $)
2020 $-80
2019 $-271
2018 $-110
2017 $-41
2016 $-42
Osmotica Pharmaceuticals Quarterly Net Income
(Millions of US $)
2021-06-30 $-18
2021-03-31 $-10
2020-12-31 $-55
2020-09-30 $-9
2020-06-30 $-13
2020-03-31 $-3
2019-12-31 $-27
2019-09-30 $-113
2019-06-30 $-125
2019-03-31 $-7
2018-12-31 $-107
2018-09-30 $-4
2018-06-30 $6
2018-03-31 $-5
2017-12-31
2017-09-30 $-12
2016-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.073B $0.178B
Osmotica Pharmaceuticals Public Limited Company operates as a biopharmaceutical company. It offers tablets, dietary supplements and drugs for the treatment of women's health. The company's product pipeline consists of Methylphenidate HCl ER 72 mg Tablets, Osmolex ER(TM), Lorzone(R), ConZip(R), Divigel(R) and OB Complete(R). Its delivery system includes Osmodex(R) drug delivery system. Osmotica Pharmaceuticals Public Limited Company is based in Bridgewater, New Jersey.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $126.808B 8.01
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $6.887B 0.00
Arcus Biosciences (RCUS) United States $3.210B 0.00
Emergent Biosolutions (EBS) United States $2.270B 8.16
Myovant Sciences (MYOV) United Kingdom $1.508B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.469B 0.00
Zymeworks (ZYME) Canada $0.850B 0.00
SQZ Biotechnologies (SQZ) United States $0.326B 0.00
Ambrx Biopharma (AMAM) United States $0.322B 0.00
Enzo Biochem (ENZ) United States $0.170B 16.71